Pharmaceuticals

Growing Pharmaceutical And Biotechnology Industries Fueling The Growth Of The Due To Rising Research And Development Investments And Demand For Advanced Therapies Is Contributing To Changes In The Meningococcal Vaccines Market

May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Meningococcal Vaccines Market Between 2026 And 2030?

The meningococcal vaccines market has seen substantial growth over recent years. It is anticipated to increase from $4.26 billion in 2025 to $4.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. Historically, this growth has stemmed from factors such as the introduction of meningococcal conjugate vaccines, an uptick in meningitis outbreaks, government immunization efforts, broader pediatric vaccination coverage, and enhanced public health funding.

The meningococcal vaccines market is anticipated to observe robust expansion over the next few years. It is projected to climb to $6.58 billion in 2030, achieving a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period can be attributed to advancements in vaccine technology, the broadening of global immunization programs, increased awareness regarding meningococcal disease, the establishment of strategic partnerships and collaborations, and a rise in vaccination initiatives for adolescents and young adults. Significant trends expected during this period include the expansion of pediatric vaccination programs, the development of broad-spectrum meningococcal vaccines, enhanced government immunization initiatives, increasing knowledge about meningococcal disease prevention, and the growth of school and college vaccination campaigns.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Major Factors Are Driving The Meningococcal Vaccines Market Forward?

Rising healthcare expenditure is anticipated to drive the expansion of the meningococcal vaccine market in the future. Healthcare, in this context, refers to residential care institutions, nursing facilities, intermediate care facilities for individuals with mental illnesses, or intermediate care facilities for people with mental retardation. The significant cost of advanced vaccine generations compared to earlier ones has become a crucial point of discussion regarding whether the benefits of these new vaccinations justify their price. Consequently, assessing the comprehensive social and economic advantages of vaccination is becoming an increasingly vital area of research in valuing vaccination. As an illustration, in April 2025, an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, indicated that Health spending in the U.S. climbed by 7.5% in 2023, reaching $4.9 trillion or $14,570 per capita. This growth rate is considerably higher than the 4.6% increase observed in 2022. Therefore, an uptick in healthcare spending is fueling the growth of the meningococcal vaccine market.

What Are The Key Segment Divisions In The Meningococcal Vaccines Market Segment Structure?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

What Trends Are Affecting The Direction Of The Meningococcal Vaccines Market?

Leading companies in the meningococcal vaccines market are engaged in developing new vaccines for the prevention of serogroups, aiming to increase their profitability. Meningococcal vaccines function as preventive measures, designed to protect individuals from infections caused by specific serogroups of the bacteria Neisseria meningitidis. As an illustration, in October 2023, Pfizer Inc., a US-based pharmaceutical company, obtained FDA approval for the vaccine PENBRAYA. Offering extensive serogroup coverage, PENBRAYA is the most comprehensive U.S.-approved meningococcal vaccine, providing protection against groups A, B, C, W, and Y. The FDA approval is rooted in strong Phase 2 and 3 trial data, which confirmed non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. Earlier, Pfizer’s September 2022 announcement disclosed positive results from a Phase 3 trial, where PENBRAYA was compared against existing licensed meningococcal vaccines in terms of its safety, tolerability, and immunogenicity.

Which Organizations Are Engaged In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Get The Full Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Geographic Region Dominates The Meningococcal Vaccines Market?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Meningococcal Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795